Navigation Links
Transgenomic Licenses IP From IntegraGen to Develop Genetic Test for Autism
Date:2/24/2010

OMAHA, Neb., Feb. 24 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder.  Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010.  Financial terms of the agreement were not disclosed.

"We are pleased to have the opportunity to develop and offer a genetic test to clinicians and parents that will assist in the evaluation of children who are thought to be at high risk of being autistic," stated Craig Tuttle, president and chief executive officer of Transgenomic. "We believe that the use of this test in conjunction with standard diagnostic tools will allow for the earlier diagnosis of autism, and importantly, the more timely initiation of treatment plans for these children.  We look forward to adding this proprietary test to our growing commercial offerings."

Autism is a developmental disorder that causes significant social, communication and behavioral challenges in children.  The Centers for Disease Control and Prevention estimates that one in 110 children in the U.S. has an autism-related disorder, and that the incidence of autism is up 57 percent from 2002 to 2006.  Even though parents typically express concerns about their child's developmental progress before the age of three, the average age of diagnoses is not until 53 months.  Early intervention has been shown to be effective in improving a child's ability to develop into a competent adult.  Children with a sibling who has been diagnosed with autism are at a significantly greater risk of developing the disorder.

"IntegraGen is excited about the opportunity for our technology to be commercialized by Transgenomic," said Dr. Bernard Courtieu, chief executive officer of IntegraGen. "We will continue our gene discovery efforts to further our understanding of autism while focusing on other diseases where molecular tests may help with patient diagnosis and disease management."

About IntegraGen

IntegraGen (www.integragen.com) is a Biotechnology Company dedicated to gene discovery which allows for the development of molecular diagnostics products and services that provide clinicians with new tools to personalize diagnosis, treatment, and therapy. IntegraGen is focused on the prevention and proactive management of complex debilitating diseases, and dedicated to addressing the needs of patients, clinicians, and advocacy groups. IntegraGen's Genetic Services Business also provides state of the art Genotyping Services to the research community. With discovery and intellectual property focused on Autism, Oncology and Metabolism, IntegraGen's Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

About Transgenomic, Inc.

Transgenomic, Inc. (www.transgenomic.com ) is a global biotechnology company specializing in high sensitivity genetic variation and mutation analysis, providing products and services in DNA mutation detection and discovery for clinical research, clinical molecular diagnostics and pharmacogenomics analyses. Its product offerings include the WAVE® Systems and associated consumables specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. With broad applicability to genetic research, over 1,475 systems have been shipped to customers in more than 30 countries. The SURVEYOR® Mutation Detection Kits and SURVEYOR Check-It Kit provide reagents and protocols for high sensitivity detection of mutations in DNA. In addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

SOURCE Transgenomic, Inc.

Back to top

RELATED LINKS
http://www.transgenomic.com
http://www.integragen.com

'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transgenomic Presents at 12th Annual BIO CEO & Investor Conference
2. Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit
3. Transgenomic, Inc. Reports Third Quarter 2009 Results
4. Transgenomic and Power3 Medical Report Identification of Abnormal Serum Proteins in Parkinsons Disease
5. Transgenomic, Inc. Reports Second Quarter 2009 Results
6. Reminder: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
8. Transgenomic, Inc. Announces Appointment of New Board Members
9. Transgenomic, Inc. Reports First Quarter 2009 Results
10. Reminder: Transgenomic Inc. Announces First Quarter 2009 Earnings Release Conference Call Webcast
11. Transgenomic and Power3 Medical Introduce NuroPro(R) Tests for Alzheimers and Parkinsons Diseases at AAN Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. , ... UTHR ) announced today that Martine Rothblatt ... Therapeutics will provide an overview and update on the ... Annual Health Care Conference. The presentation will ... a.m. Eastern Time, and can be accessed via a ...
(Date:4/27/2016)... ... 2016 , ... A compact PET scanner called NuPETâ„¢ has ... Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary imaging ... Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers who ...
(Date:4/27/2016)... 27, 2016 ReportsnReports.com adds ... specific focus on US, EU, China ... to the healthcare business intelligence collection of its ... Complete report on the Flow Cytometry market spread ... with 282 tables and figures is now available ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg Instruments, a ... technology innovation for its Volume Pattern Generator (VPG) line of lithography systems. The ... photomasks as well as a solution for mid volume direct write lithography applications. ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):